Business Wire

Entersekt Announces Jon Roskill as New Board Member, Key Leadership Hires, and Accelerated Global Expansion

Share

Entersekt, a global leader in customer and payment authentication solutions for financial fraud prevention, today announced the appointment of Jon Roskill, former Acumatica CEO and Microsoft executive, to its board of directors as part of its continued expansion within North America. In late 2021, Entersekt received significant funding from Accel-KKR, a technology-focused private equity firm, to hire key leadership, launch new branding, and accelerate the expansion within this region.

Jon Roskill joins Entersekt board of directors

A former Corporate Vice President at Microsoft, and CEO of Acumatica, Mr. Roskill brings decades of executive and advisory experience to the Entersekt board as the company continues to introduce advanced customer and payment authentication solutions into the North American market as part of its global expansion. He currently serves as a Senior Advisor with EQT Partners after spending eight years with Acumatica, a cloud ERP provider.

“Jon joins our board of directors at a critical time. Entersekt is at an inflection point in our growth and expansion, particularly in North America,” said Schalk Nolte, CEO of Entersekt. “His vast experience in global go-to-market strategies will bring tremendous value to the company.”

“Entersekt has a tremendous opportunity ahead of it, and I’m excited to be joining at such a pivotal time in its growth” added Roskill. “With proven, patented technologies, excellent leadership, a strong, global customer base and solid financial foundation, I look forward to being a part of Entersekt’s next phase as it establishes itself as a global leader in financial fraud prevention.”

Expansion of the leadership team to drive bullish growth strategy

In addition, Entersekt has also hired new additions to the management team to support and accelerate the speed to market of Context Aware™ Authentication in North America. Key hires include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.

The new team brings with them the following strong leadership experience in the financial services industry:

  • Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank and Mastercard.
  • Sampath holds a 25-year track record in scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
  • Moreno’s experience includes senior marketing leadership roles spanning over 20 years with companies such as Bottomline and Datawatch.

New strategic partnerships as global growth enablers

Many new integrations and partnerships with strategic technology providers are currently underway. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform. Q2 is a leading provider of digital transformation solutions for banking and lending. By supporting pre-integration, these partnerships enable banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology.

Targeting the demand for enhanced security

A recent Forrester Survey of 300 North American fraud prevention decision-makers, reported that all respondents had experienced authentication fraud in the past year. “The investment from Accel-KKR will support the significant market opportunity and demand for the cloud-first, global authentication solutions that Entersekt is known for. We have a strong leadership team in place that will play a critical role in accelerating our business vision to expand and scale into this territory”, concludes Nolte.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Tharusha Pillay
tharusha@entersekt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye